Analysis of long-term results of conservative and surgical treatment in patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses
- Authors: Zhao J.1, Mudunov A.M.1,2, Aliyeva S.B.3, Kamolova F.S.4, Stelmakh D.K.3, Gelfand I.M.3
-
Affiliations:
- Sechenov University, Ministry of Health of Russia
- Lapino Clinical Hospital of the “Mother and Child” Group of companies
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- A.S. Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department
- Issue: Vol 14, No 2 (2024)
- Pages: 48-56
- Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
- Published: 03.08.2024
- URL: https://ogsh.abvpress.ru/jour/article/view/980
- DOI: https://doi.org/10.17650/2222-1468-2024-14-2-48-56
- ID: 980
Cite item
Full Text
Abstract
Introduction. Surgical intervention with subsequent chemoradiation therapy is one of the treatment standards in squamous cell carcinoma of the nasal cavity and paranasal sinuses. However, the question of the optimal therapy for this pathology remains open.
Aim. To compare treatment results in patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses after conservative and surgical treatment.
Materials and methods. The study included 86 patients with squamous cell carcinoma of the nasal cavity and paranasal sinuses, stages III–Iva, who between 2000 and 2020 received treatment at the N.N. Blokhin National medical Research Oncology Center. Surgical treatment with subsequent radiation or chemoradiation therapy was performed in 31 patients, conservative treatment (radiation or chemoradiation therapy) was performed in 55 patients.
Results. Five-year overall survival in the conservative treatment group was 46.2 %, in the surgical treatment group – 59.7 % (р = 0.081); 5-year progression-free survival was 17 and 50.5 %, respectively (p = 0.002). In patients with Т3N0 tumor who received surgical treatment, 5-year progression-free survival was significantly higher than in patients who received conservative treatment (p <0,05). Comparison of overall survival and progression-free survival of patients who achieved objective response (complete response + partial response) after conservative treatment (n =36) and after surgical treatment (n = 31) did not show statistically significant differences (р = 0.469 and р = 0.183, respectively). The overall 5-year survival rate in the salvage surgery treatment group (24/55) was 63.1 % compared with 59.7 % in the surgical treatment group (n = 31), there were also no significant differences (p = 0.95). In patients with T3 tumor who received conservative treatment in this study, higher risk of progression was observed compared to patients who underwent surgical treatment.
Conclusion. Surgical intervention remains an important treatment method for patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses, especially in cases of smaller tumor extent. Conservative therapy seems promising but large-scale prospective controlled randomized clinical trials are necessary to confirm its effectiveness and safety in various patient groups.
About the authors
J. Zhao
Sechenov University, Ministry of Health of Russia
Author for correspondence.
Email: karychou@mail.ru
ORCID iD: 0000-0001-8599-5809
Jiahui Zhao
Bld. 4, 2 Bolshaya Pirogovskaya St., Moscow119991
Russian FederationA. M. Mudunov
Sechenov University, Ministry of Health of Russia; Lapino Clinical Hospital of the “Mother and Child” Group of companies
Email: fake@neicon.ru
ORCID iD: 0000-0002-0918-3857
Bld. 4, 2 Bolshaya Pirogovskaya St., Moscow119991; 111 1st Uspenskoe Shosse, Lapino Village 143081, Odintsovo Dst., Moscow Region
Russian FederationS. B. Aliyeva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-6835-5567
24 Kashirskoe Shosse, Moscow 115552
Russian FederationF. Sh. Kamolova
A.S. Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department
Email: fake@neicon.ru
ORCID iD: 0000-0002-6832-9780
Bld. 6, 86 Shosse Entuziastov, Moscow 111123
Russian FederationD. K. Stelmakh
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-6178-2777
24 Kashirskoe Shosse, Moscow 115552
Russian FederationI. M. Gelfand
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-4496-6128
24 Kashirskoe Shosse, Moscow 115552
Russian FederationReferences
Supplementary files


